151 related articles for article (PubMed ID: 38029041)
1. Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy.
Tanizaki J; Kuroda H; Yokoyama T; Takahama M; Shoda H; Nakamura A; Kitamura Y; Mamesaya N; Kadota Y; Sawa K; Okishio K; Okada M; Suminaka C; Noda K; Sakai K; Chiba Y; Nishio K; Chamoto K; Honjo T; Yamamoto N; Nakagawa K; Hayashi H
JTO Clin Res Rep; 2023 Dec; 4(12):100590. PubMed ID: 38029041
[TBL] [Abstract][Full Text] [Related]
2. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
[TBL] [Abstract][Full Text] [Related]
3. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis.
Scirocchi F; Strigari L; Di Filippo A; Napoletano C; Pace A; Rahimi H; Botticelli A; Rughetti A; Nuti M; Zizzari IG
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430974
[TBL] [Abstract][Full Text] [Related]
4. Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody.
Murakami S; Shibaki R; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Ohe Y
Thorac Cancer; 2020 Dec; 11(12):3585-3595. PubMed ID: 33108686
[TBL] [Abstract][Full Text] [Related]
5. Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
Tiako Meyo M; Jouinot A; Giroux-Leprieur E; Fabre E; Wislez M; Alifano M; Leroy K; Boudou-Rouquette P; Tlemsani C; Khoudour N; Arrondeau J; Thomas-Schoemann A; Blons H; Mansuet-Lupo A; Damotte D; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32085544
[TBL] [Abstract][Full Text] [Related]
6. Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.
Kawakami H; Sunakawa Y; Inoue E; Matoba R; Noda K; Sato T; Suminaka C; Yamaki M; Sakamoto Y; Kawabata R; Ishiguro A; Akamaru Y; Kito Y; Yabusaki H; Matsuyama J; Takahashi M; Makiyama A; Hayashi H; Chamoto K; Honjo T; Nakagawa K; Ichikawa W; Fujii M
Eur J Cancer; 2023 May; 184():10-20. PubMed ID: 36889037
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients.
Omura Y; Toiyama Y; Okugawa Y; Yin C; Shigemori T; Kusunoki K; Kusunoki Y; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Ohi M; Kusunoki M
Cancer Immunol Immunother; 2020 Dec; 69(12):2533-2546. PubMed ID: 32577816
[TBL] [Abstract][Full Text] [Related]
8. Soluble immune checkpoints CTLA-4, HLA-G, PD-1, and PD-L1 are associated with endometriosis-related infertility.
Santoso B; Sa'adi A; Dwiningsih SR; Tunjungseto A; Widyanugraha MYA; Mufid AF; Rahmawati NY; Ahsan F
Am J Reprod Immunol; 2020 Oct; 84(4):e13296. PubMed ID: 32593225
[TBL] [Abstract][Full Text] [Related]
9. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M
Front Immunol; 2020; 11():580335. PubMed ID: 33224142
[TBL] [Abstract][Full Text] [Related]
10. Decreased serum soluble programmed cell death ligand-1 level as a potential biomarker for missed miscarriage.
Li Q; Chen C; Wu J; Poon LC; Wang CC; Li TC; Zhang T; Guo X; Song L; Wang X; Zhang Q; Ye Z; Yang Y; Lu J; Yao J; Ye D; Wang Y
Hum Reprod; 2023 Nov; 38(11):2128-2136. PubMed ID: 37671597
[TBL] [Abstract][Full Text] [Related]
11. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
[TBL] [Abstract][Full Text] [Related]
12. Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer.
Sun J; Qiu MZ; Mei T; Gao Y; Chang B; Zhang Y; Wang FH; Li S
Transl Cancer Res; 2020 Apr; 9(4):2434-2448. PubMed ID: 35117603
[TBL] [Abstract][Full Text] [Related]
13. Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.
Himuro H; Nakahara Y; Igarashi Y; Kouro T; Higashijima N; Matsuo N; Murakami S; Wei F; Horaguchi S; Tsuji K; Mano Y; Saito H; Azuma K; Sasada T
Cancer Immunol Immunother; 2023 Aug; 72(8):2829-2840. PubMed ID: 37188764
[TBL] [Abstract][Full Text] [Related]
14. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Liao G; Zhao Z; Qian Y; Ling X; Chen S; Li X; Kong FS
Front Oncol; 2021; 11():774131. PubMed ID: 35004295
[TBL] [Abstract][Full Text] [Related]
16. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Zhou J; Mahoney KM; Giobbie-Hurder A; Zhao F; Lee S; Liao X; Rodig S; Li J; Wu X; Butterfield LH; Piesche M; Manos MP; Eastman LM; Dranoff G; Freeman GJ; Hodi FS
Cancer Immunol Res; 2017 Jun; 5(6):480-492. PubMed ID: 28522460
[TBL] [Abstract][Full Text] [Related]
17. Soluble sPD-L1 and Serum Amyloid A1 as Potential Biomarkers for Lung Cancer.
Jovanović D; Roksandić-Milenković M; Kotur-Stevuljević J; Ćeriman V; Vukanić I; Samardžić N; Popević S; Ilić B; Gajić M; Simon M; Simon I; Spasojević-Kalimanovska V; Belić M; Mirkov D; Šumarac Z; Milenković V
J Med Biochem; 2019 Jul; 38(3):332-341. PubMed ID: 31156344
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Cancer Immunol Immunother; 2023 Nov; 72(11):3755-3764. PubMed ID: 37646826
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy.
Zhao J; Zhang P; Wang J; Xi Q; Zhao X; Ji M; Hu G
Medicine (Baltimore); 2017 Feb; 96(7):e6102. PubMed ID: 28207525
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010).
Kenmotsu H; Sugawara S; Watanabe Y; Saito H; Okada M; Chen-Yoshikawa TF; Ohe Y; Nishio W; Nakagawa S; Nagao H
Cancer Sci; 2022 Dec; 113(12):4327-4338. PubMed ID: 36062851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
